The Association of Immune and Liver Functions in Mycoplasma Pneumoniae Pneumonia Children with Andrographolide Sulfonate's Therapy.

BACKGROUND: The aim of this study was to explore the association of immune and liver functions' alteration in mycoplasma pneumoniae pneumonia (MPP) children with the therapeutic effect of andrographolide sulfonate's curative outcome. METHODS: From January 2019 to April 2021, a group of 102 MPP child patients was divided into severe and mild cases in the light of the disease's severity, and involvement of 57 healthy child patients during the identical period was as the control. Comparison of immune function among three groups [immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM)] and liver function indexes [Alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyl transferase (GGT)] was to analyze its association and assessment value for the illness's severity. RESULTS: IgA and IgM in MPP child patients were declined with the illness's severity, while ALT, AST and GGT were elevated with it (p < 0.05). AUC of combined detection of immune and liver function indexes in assessing MPP's severity in children was augmented vs. each index's alone examination (p < 0.05). IgA was negatively associated with MPP's severity in children, while ALT, AST, and GGT were positively associated with it (p < 0.05). IgA in the effective was augmented vs. the noneffective, while ALT, AST, and GGT were declined vs. the noneffective (p < 0.05). CONCLUSIONS: The immune and liver functions of MPP child patients are associated with the illness's severity and provide an assessment value for the disease's severity and Andro-S's curative outcome.

Clinical Efficacy and Immune Function of Andrographolide Sulfonate in Children with Mycoplasma Pneumoniae Pneumonia.

BACKGROUND: To figure out the effect of andrographolide sulfonate on the clinical efficacy and immune function of children with mycoplasma pneumoniae pneumonia (MPP). METHODS: From January 2019 to April 2021, a total of 102 children with MPP were selected as the research group. They were assigned into the control and the observation groups by random number table method, with 51 cases/group. The control group was given routine treatment, and the observation was given andrographolide sulfonate treatment. The therapeutic efficacy and improvement of clinical symptoms were compared between the two. The changes of immune function, pulmonary function, myocardial enzymology indexes, MCP-4, IL-1ß, IFN-γ, and TNF-α were noticed in the groups before and after treatment. The presence of drug-related adverse reactions of patients was recorded during treatment. RESULTS: The total effective rate of treatment in the observation group was higher, and the time of fever reduction, pulmonary rales disappearance and cough disappearance time were all shorter vs. the control group (p < 0.05). Immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) in the observation group after treatment were higher, and monocyte chemoattractant protein 4 (MCP-4), interleukin-1ß (IL-1ß), interferon-γ (IFN- γ), and tumor necrosis factor-α (TNF-α) were reduced vs. the control group. The forced expiratory volume in the 1st second (FEV1) and the percentage of forced vital capacity occupied by the forced expiratory volume in the first second (FEV1/FVC) and peak expiratory flow (PEF) values were higher (p < 0.05), but aspartate aminotransferase (AST), lactate dehydrogenase (LDH), and creatine kinase (CK) and isoenzyme (CK-MB) were reduced in the observation group after treatment vs. the control group (p < 0.05); No serious adverse reactions took place in the two during treatment. CONCLUSIONS: The treatment of andrographolide sulfonate in children with MPP can enhance the therapeutic effect, ameliorate the immune function and lung function of children, and reduce inflammation and myocardial enzymes.

[Myelodysplastic syndrome with early presentation of refractory monolineage cytopenia-with report of 13 cases].

To find the relationship between myelodysplastic syndrome (MDS) and refractory monolineage cytopenia, thirteen cases of MDS with early presentation of monolineage refractory cytopenia were analyzed retrospectively. The results were as follows: (1) The percentage of 13 cases with refractory monolineage cytopenia were 5.9% of the total 219 MDS patients in the past 10 years. (2) The median time of patients with monlineage cytopenia to M DS diagnosed was 48.5 +/- 55.3 months. The median times from monolineage cytopenia to MDS diagnosed for patients with neutropenia, erythrocytopenia and thrombocytopenia were 12.5 +/- 9.5 months, 53.8 +/- 54.6 months and 59.2 +/- 65.5 months, respectively. (3) The common characteristics of 13 cases were as follows: (a) the macrocytic erythrocytes in peripheral blood and the percentage of intermediate and late erythroblast in bone marrow were increased; (b) occasionally few cells with dysplasia could be found; (c) all patients with erythrocytopenia and thrombocytopenia transformed to RA and RAS while the most of patients with neutropenia transformed to RAEB subtype; (d) autoantibody could be found in part of the patients. It is concluded that some of refractory monolineage cytopenias in essence are the early states of MDS.